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ABSTRACT
A stepped wedge design is a randomized controlled trial design with a phased intro-
duction of the intervention at different moments of the trial. It has attracted a lot of
interests from medical researchers and epidemiologists and much debate has been
focusing on the practical aspect of the design while the statistical analysis was less
addressed. The objective of the presented study is to evaluate statistical methods for
analysing binary outcome data arising from a stepped wedge clustered randomized
trial in a systematic and expository manner. We included statistical methods that
are not commonly considered in the stepped wedge design literature and highlight
some of the limitations of the current commonly used methods. Specifically, we con-
sidered an aggregate-data meta-analysis approach when no period effect exists, a
marginal model with generalized estimating equations at a cluster level, Hussey and
Hughes variance components model at both individual level and cluster level, and a
subject specific growth model at individual level. Simulations were conducted to
compare the performances of these methods under varying assumptions about the
period effects and period-treatment interaction effects. Simulation results showed
that the marginal model and the meta-analysis approach were both valid choices as
aggregated-level data analysis approach, but the former one can also be used when a
period effect is present. Furthermore, the linear mixed model of Hussey and Hughes
provided biased estimates of the treatment effect when a period-treatment interac-
tion was ignored. Even when a period-treatment interaction would be taken into
account, the model still did not have the correct interpretation due to parametriza-
tion issues, possibly leading to incorrect inferences in practice. A subject-specific
growth model that took time period as continuous variable had a straightforward






A stepped wedge design is a randomized controlled clinical trial de-sign which utilizes a randomized sequential roll-out of the intervention.[12]
At the beginning of the trial, participants will start with the control treat-
ment. Switching the treatment to the new intervention will take place at
predetermined switching moments. At the end of the trial, the treatment
arm consists of the new intervention only. Though not per definition, the
stepped wedge design is most often randomized at cluster level. Therefore,
the clustered randomized stepped wedge design will be the focus of the
presented paper. Advantages of the stepped wedge design, including logis-
tical flexibilities, efficiencies in terms of power and sample size compared
to traditional (clustered) parallel group designs, and the ethical advan-
tages in longitudinal and open cohort studies, have been recognized.[1–3]
Therefore, stepped wedge designs have been increasingly adopted by
medical researchers. As such, much debates have been focusing on the
practical aspects of the design.[3, 7, 15, 21, 23, 32]
However, the statistical methodology for the analysis of the stepped
wedge design is still “in its infancy”.[11] In terms of data analysis methods,
stepped wedge designs are quite unique. Unlike parallel group designs,
randomization units in the stepped wedge design are no longer being
allocated to distinct treatment arms for comparison. Stepped wedge
designs are also different from crossover designs since the switching is
in one direction only. Due to the unique character of the stepped wedge
design, it is unclear and sometimes confusing which statistical methods
should be used in a stepped wedge design.[8] The most frequently applied
statistical methods are developed by Hussey and Hughes.[20] However,
their linear mixed model assumes a constant treatment effect across
clusters and over periods and they may not be applicable for all studies.
A recent study found that the estimated treatment effects had up to 50%
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biases when models are misspecified in the presence of heterogeneous
treatment effects at different clusters.[25]
The literature is sparse on the analysis of stepped wedge designs when
treatment-period interactions would be present. Additionally, outcomes
other than normally distributed variables have hardly been addressed.
Alternative analysis methods, other than Hussey and Hughes [20](and
its extension by Hemming and Girling [10]), have not been proposed yet
either. This indicates the need to study current methods under more
realistic settings and to expand the tool set for analysis of stepped wedge
design. Therefore, we will use simulation studies to illustrate some of the
commonly proposed data analysis methods for the stepped wedge design
and examine the validity of these methods.
3.2. METHODS
Data analysis of stepped wedge designs can be broken down into two
distinct categories. Either the data can be analysed at an aggregated level
by taking summary measures at cluster-period combination; or the data
can be analysed at an individual level. Both approaches have to address
possible confounding issues of period and treatment effects, since in the
stepped wedge design, period is associated with both the outcome and the
treatment. Several approaches within the two categories will be discussed
in more detail.
3.2.1. AGGREGATED-DATA ANALYSIS
In clustered randomized trials, outcomes may be summarized into one
measure for each cluster across the whole period [4] but in clustered
randomized stepped wedge design studies, a cluster-period measure is
needed to be able to deal with treatment and period effects. Let Yi j k be




gate measure is then Mi j ≡ M(Yi j 1, · · · ,Yi j ki j ) with Mi j for instance the
average or median.
WITHOUT PERIOD EFFECTS
In case there is no period effect, the aggregate measure can be further
summarized over the periods that belong to the same treatment. This
results into a pair (MCi , M
T
i ) for the control and treatment at cluster i . In
this way, each cluster will contribute to the overall effect size. For instance,
for continuous outcomes Yi j k , the effect size can be the difference M
C
i −




i , but for binary outcomes Yi j k the odds ratio
M Ti (1−MCi )/MCi (1−M Ti ), with M Xi the average for treatment X , can be
used. Consequently, the whole trial can be viewed as a meta-analysis study
and any appropriate method for synthesizing effect sizes can be applied to
this situation (see for example [9]). However, such approach does require
an appropriate estimator for the standard error of the selected effect size.
If it is calculated from the standard errors on MCi and M
T
i , it is important
to mention that the standard errors for MCi and M
T
i will not be the same,
as the measures will be calculated from different numbers of observations.
The numbers of periods before the switch are typically different from
the numbers of periods after the switch. Alternatively, meta-analysis
methods can also be directly applied to the pair (MCi , M
T
i ) considering
a joint distribution. Such joint model is typically preferred for binary
outcomes Yi j k . The measure M
X
i will be taken as the number of events
for treatment X and the pair (MCi , M
T
i ) will be considered independently
binomially distributed conditionally on cluster i .[16, 17] A pooled odds
ratio is then estimated from this generalized linear mixed model, which
would indicate the treatment effect.







in case of normally distributed outcomes, but proposed a paired t-test in-
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a weighted average approach on the effect size Y¯i
C − Y¯i T . Even though
the pooled effect size through the paired t-test proposed by Hussey and
Hughes is still correct, it is not as efficient as the weighted average on the
effect sizes.[6]
WITH PERIOD EFFECTS
In case of the presence of period effects, outcomes cannot be summa-
rized into a control-treatment pair for each clusters. This means that
the analysis should be conducted on Mi j instead of Mi where Mi j rep-
resents a summary of Yi j 1, · · ·Yi j ki j . There are two approaches. In the
first approach, variations between clusters are treated as nuisances and
a marginal model with generalized estimating equations [31] can be ap-
plied. The cluster functions as the unit with repeated observations and
both period and treatment enter the analysis as fixed effects. The focus
of the approach is the inferences of the fixed effects averaged over the
clusters.[24] The second approach is to consider a subject-specific mixed
effects model with clusters as random effect and period and treatment
again as fixed effects.[10, 20]
The relative merits of the two methods are well-discussed in litera-
ture.[22, 28, 30] In general, the marginal model approach does not rely on
the assumption of the correlation structure and is robust against misspec-
ification. However, when the number of clusters is small, the empirical
“sandwich” estimator [19, 22, 29] used in the model underestimates the
true (co)variances of the parameters and the Wald-type test is subject
to inflated Type-I error. On the other hand, the mixed effects model ap-
proach is sensitive to the specification of the covariance structure and the
treatment effect is more difficult to interpret on a population level.
Incorporating period effects in both approaches will be further dis-






The majority of the stepped wedge trials use an individual-level approach
as their primary analysis methods. When there is no period effect, stan-
dard statistical models can be applied taking into account the possible
correlations within clusters. However, in case of period effects, the analy-
sis of data collected within a stepped wedge trial will be more complicated
due to the time-dependent nature of the treatment switches. Though
model specification is usually trial-specific, several general points can
be made. Considering a generalized linear mixed model, there are two
approaches to take period into account. Either, period can be included in
the model as a categorical variable and then a piecewise constant effect
for each period can be assumed. Alternatively, a functional form can be
specified for the period effects by considering period as a continuous vari-
able and a “growth” model can be specified. Both approaches has its own
benefits and drawbacks. The piecewise constant approach is supposed to
be less precise, but more flexible and less sensitive to misspecifications
of the period effects. Whilst the growth model will be more precise, it is
deemed to be problematic when an incorrect functional form is chosen
for the period effects.
Another challenge in the analysis of data collected within a stepped
wedge trial is the interaction between treatment with periods. This is
infrequently discussed in current literature.[13] One of the main issues
with interaction of treatment and period is that there is no intervention
at the first period and no control at the last period in a stepped wedge
trial. At least in the last period, a period-specific treatment effect is al-
ways accompanied by a period effect and therefore it is not identifiable.
Treatment-period interaction can only be assessed for the periods that
contain both intervention and control treatment. This has direct conse-
quences for the parameter estimation. If there exists treatment-period
interaction which is not taking into account, the estimated treatment and
346 3. STATISTICAL ANALYSIS
period effects will be biased (as we will see later).
In case the treatment-period interactions are included in the model,
then a fully parametrized model will not be identifiable. Consider a full
model parametrized as in the Table 3.1 for a stepped wedge design with
5 periods and 4 switch moments. The mean response at each cell is
expressed in terms of combinations of a general mean µ, period effect b j ,
overall treatment effect θ, and a period-specific treatment effect δ j as a
difference with respect to the overall treatment effect. There are 8 unique
cells but 11 parameters are specified.
Table 3.1 | Visualization of the full parametrization with treatment-period interaction
for a stepped wedge design with 5 periods and 4 switch moments
Switch Period 1 Period 2 Period 3 Period 4 Period 5
Switch 1 µ+b1 µ+b2+θ+δ2 µ+b3+θ+δ3 µ+b4+θ+δ4 µ+b5+θ+δ5
Switch 2 µ+b1 µ+b2 µ+b3+θ+δ3 µ+b4+θ+δ4 µ+b5+θ+δ5
Switch 3 µ+b1 µ+b2 µ+b3 µ+b4+θ+δ4 µ+b5+θ+δ5
Switch 4 µ+b1 µ+b2 µ+b3 µ+b4 µ+b5+θ+δ5
To solve the identifiability problem, it is required to eliminate 3 param-
eters by setting these parameters to zero in the model or put constrains on
them. One possible specification is described as follow. First, for the cells
under the control, there are 4 unique cells and 5 specified parameters
(one mean µ and 4 period effect b1, b2, b3 and b4). Since b1 and µ can
not be estimated separately, we choose to set b1 = 0. Given that, µ can be
estimated from the cells of period 1. Once µ is estimable, one can also
estimate b2, b3, and b4 for the cells without treatment at period 2, 3 and 4.
Considering the cells under the treatment, there are now 4 unique cells
with 6 parameters. As in the last period, period 5, the treatment effect δ5
is always accompanied by the period effect b5, one could elect to set b5
to zero. Then, there are still 3 unique cells left in period 2, period 3 and
period 4 with four unknown parameters. Thus it is necessary to eliminate




period to observe a treatment effect, it might be reasonable to consider
this period as a reference level. The above mentioned choices would then
yield a system of identifiable parameters as is shown in Table 3.2.
Table 3.2 | Visualization of the identifiable parametrization with treatment-period inter-
action for a stepped wedge design with 5 periods and 4 switch moments
Switch Period 1 Period 2 Period 3 Period 4 Period 5
Switch 1 µ µ+b2+θ µ+b3+θ+δ3 µ+b4+θ+δ4 µ+θ+δ5
Switch 2 µ µ+b2 µ+b3+θ+δ3 µ+b4+θ+δ4 µ+θ+δ5
Switch 3 µ µ+b2 µ+b3 µ+b4+θ+δ4 µ+θ+δ5
Switch 4 µ µ+b2 µ+b3 µ+b4 µ+θ+δ5
However, setting b5 to zero is essentially assuming that period 1 and
period 5 have the same effect while other periods in between having
different effects. This is a rather obscured assumption to make in prac-
tice. As an alternative, we could elect to put constrains on the function
form of the treatment-period interaction effects. For instance, it is some-
times reasonable to assume that the differences between different period-
specific treatment effects are on average zero, namely heterogeneity of
the treatment effect. Such assumption can be reflected by restricting
our model using δ2+δ3+δ4+δ5 = 0. This is the same thing as setting
δ5 = −(δ2 +δ3 +δ4). Note that since we have already set δ2 zero, this
is equivalent to δ5 = −(δ3+δ4). In this case, it might be preferable to
consider treatment as random across period instead of using the pro-
posed parametrization for treatment-period interaction terms. On the
other hand, in certain trials, it is expected that treatment effect would
improve/deteriorate over periods with a linear trend, it is then possible to
assume δ3−δ2 = δ4−δ3 = δ5−δ4 =∆, namely a constant increment for
the treatment-period interactions.
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3.3. SIMULATION
3.3.1. SIMULATION AND ANALYSIS
To demonstrate the points discussed in the method section, a simulation
study was conducted. First of all, a cross-sectional stepped wedge design
with 20 clusters, 4 switch points (5 clusters per switch points), and 5 time
periods were considered. A cross-sectional design means that participants
will not be followed during the trial and at each period new participants
will enter the trial. For each cluster, 100 patients were simulated at each
period with a binary outcome using the following generalized linear mixed
model:
logit(pii j k )=µ+ai +b j + (θ+δ j ) · xi j
where pii j k is the probability of experiencing the event for patient k
at period j in cluster i , µ is the intercept at baseline (or the mean at the
first period), ai is a random effect for cluster i sampled from N (0,σ2c ), b j
is an effect of the j th period, θ+δ j is a period-specific treatment effect
consisting of the overall treatment effect θ and δ j the difference with
respect to the overall treatment effect, and xi j is the treatment indicator
(xi j = 1 means under the intervention and 0 otherwise). The variance σ2c
of the random effect ai was set to 0.25.
We first considered two scenarios without treatment period interaction
effects (θ = −0.2 and δ j = 0 for all periods). In scenario I, we assumed
that all b j ’s are equal to 0 (no period effects) and for scenario II we as-
sumed a linear trend in the period effects (b j = 0.2 j ). Furthermore, we
also considered two scenarios where the treatment-period interaction
is both not zero. In these scenarios, we incorporated the same period
effect as scenario II with b j = 0.2 j . In scenario III, a linear treatment-




scenario IV the treatment-period interaction is considered as a random
effect with θ =−0.2 and δ j sampled from a normal distribution N (0,0.25).
A summary of the four simulation settings is provided in Table 3.3
Table 3.3 | Summary of the four simulation scenarios
Scenario Period effect Treatment period interaction Average treatment effect
I 0 0 -0.2
II b j = 0.2 j 0 -0.2
III b j = 0.2 j θ j =−0.2−0.3 j -1.25
IV b j = 0.2 j θ j ∼N (−0.2,0.25) -0.2
For all scenarios, the data was analyzed at both cluster and individual
level. For the cluster-level approach, a meta-analysis approach was first
considered by treating each cluster as a sub-study and we applied the
Mantel-Haenszel method for the overall odds ratio. Secondly, we used a
marginal model with generalized estimating equation on the aggregated
event counts at cluster-period level using the binomial distribution and
treat period as a categorical variable. Furthermore, a generalized linear
mixed model was fitted to the aggregated data. At individual level, three
different generalized linear mixed models were fitted to the simulated
data. First, we used the variance component model from Hussey and
Hughes which does not include the treatment-period interaction term.
Secondly, we fitted the Hussey and Hughes model with additional terms
for the treatment-period interactions. In addition, we fitted the Hussey
and Hughes model with a constant increment in period-specific treatment
effects ∆ instead of the interaction term. Furthermore, a generalized
linear mixed model which considers the treatment-period interaction
term as a random effect is also included. Finally, we used a linear growth
model by treating the period as continuous and with a slope dependent
on treatment. For all models except for the Mantel-Haenszel method,
clusters were considered as random as well. Additional hypothesis testing
of the treatment-period interactions was made for models that take into
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account the interactions based on Type III test.
Mean and standard deviation of the parameter estimations and their
empirical coverage probabilities were summarized from 2000 simulations.
ALL simulations were conducted in SAS® 9.4. Mantel-Haenszel estima-
tor of the odds ratio was computed via PROC FREQ. The Greenland and
Robins variance estimator for ln(ORM H ) was used to compute the confi-
dence intervals of the Mantel-Haenszel estimates of the common odds
ratios. For the marginal model with generalized estimating equations,
PROC GENMOD was used and coverage probabilities were based on the
Wald-type confidence intervals. For the generalized linear mixed models,
PROC GLIMMIX was used with the coverage probabilities derived based
on the t-type confidence intervals and the denominator degrees of free-
dom calculated by the default containment method. Wherever applicable,
period 1 is always considered as the reference category in the analysis. For
other variables, we followed the default parametrizations of the software
package.
3.4. RESULTS
Simulation results of each method under the four scenarios are shown
in Table 3.4 - Table 3.11, respectively. Due to the setting of the simulated
stepped wedge design, the information with regarding to the treatment-
period interactions can only be drawn from the three periods that have
both treatment and control. Thus the inferences of the variance com-
ponents of the interaction terms in the generalized linear mixed model
with random treatment-period interactions were highly unreliable and
is therefore omitted in the table. In scenario I, namely when there is no
period effect, the cluster-level approaches all produced unbiased esti-
mates of the treatment effect. It should be noted that since the marginal




responding mean estimation for the subject-specific treatment effect is
approximately −0.1884
√
1+0.346σ2c =−0.1964.[18] This correction also
explains the lower coverage probabilities. Individual level approaches all
had unbiased estimations of the treatment effect and nominal coverage
probabilities. When a secular trend was introduced into the data gener-
ation process (scenario II), the Mantel-Haenszel approach, that did not
take into account the period effects, produced biased estimates of the
treatment effect. Its results are therefore not presented in all scenarios
with period effects. All other models had unbiased estimations of the
treatment effect and the period effects. Except for the random interaction
model, all other models had nominal coverage probabilities. The ran-
dom interaction model, on the other hand, had too conservative coverage
probabilities.
Table 3.4 | Mean, standard deviation and the empirical coverage probabilities of different
methods for scenario (I): No period effect and no treatment-period interaction (Origi-
nally estimated intercept, period effects and treatment-period interaction terms from
various models were suppressed for compactness)





Mantel-Haenszel Odds ratio 0.8187 0.8214 0.0406 95.00%
Cluster: Marginal Treatment -0.2 -0.1884 0.0781 91.50%
Cluster: Mixed Treatment -0.2 -0.1974 0.0818 94.74%
H&H (no interaction) Treatment -0.2 -0.1972 0.0817 94.35%
H&H (interaction) Treatment -0.2 -0.1986 0.1275 96.05%
Constant increment Treatment -0.2 -0.1963 0.1177 95.45%
Growth model Treatment -0.2 -0.2017 0.1561 95.00%
In scenario III when a linear treatment-period interaction effect was
introduced, all models that do not take into account the interactions
estimated the parameters with biases. The true value of the treatment
effect was taken as the average of the four period-specific treatment effects
among period 2 to 5. However, it was peculiar that the models without the
interaction term were not able to estimate the average treatment effect as
it would for the parallel group design situation. Apparently the average
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Table 3.5 | Bias, standard deviation (SD) and the empirical coverage probabilities (CP)
of three different methods without interactions for scenario (II): Period effect and no
treatment-period interaction.
Cluster: Marginal Cluster: Mixed H&H Model
Parameters* bias (SD) CP bias (SD) CP bias (SD) CP
Treatment 0.0073 (0.0915) 92.10% 0.0001 (0.0942) 95.49% 0.0000 (0.0941) 94.95%
Intercept 0.0620 (0.1179) 90.20% 0.0066 (0.1216) 96.14% 0.0064 (0.1216) 96.15%
Period 2 0.0097 (0.0787) 92.35% 0.0025 (0.0816) 94.84% 0.0025 (0.0817) 94.40%
Period 3 0.0155 (0.0915) 90.00% 0.0010 (0.0947) 94.69% 0.0010 (0.0947) 94.25%
Period 4 0.0237 (0.1071) 89.60% 0.0024 (0.1104) 95.04% 0.0024 (0.1104) 94.55%
Period 5 0.0271 (0.1231) 90.95% 0.0007 (0.1267) 95.34% 0.0007 (0.1266) 94.90%
* Originally estimated treatment-period interaction terms were suppressed for compactness
Table 3.6 | Bias, standard deviation (SD) and the empirical coverage probabilities (CP) of
three different methods with interactions for scenario (II): Period effect and no treatment-
period interaction.
H&H model with interaction Constant increment Growth Model
Parameters* bias (SD) CP bias (SD) CP bias (SD) CP
Treatment 0.0044 (0.1590) 94.80% 0.0015 (0.1309) 95.30% 0.0048 (0.1768) 95.45%
Intercept 0.0064 (0.1216) 96.10% 0.0064 (0.1216) 96.10% 0.0064 (0.1360) 96.15%
Period 2 0.0022 (0.0869) 94.80% 0.0025 (0.0855) 94.60%
0.0008 (0.0405) 94.50%
Period 3 0.0008 (0.1051) 94.70% 0.0008 (0.0947) 94.25%
Period 4 0.0019 (0.1487) 95.55% 0.0000 (0.1373) 95.10%
Period 5 0.0050 (0.1800) 94.75% 0.0050 (0.2400) 95.10%




treatment effect can no longer be estimated by these models without
interaction term for stepped wedge designs. It is worth mentioning that
the default parametrization of the software package for the Hussey and
Hughes model with treatment-period interaction was different from the
one described in Table 3.2. It had taken δ4 = 0, and δ5 = 0 which means
that the estimated treatment effect now has a interpretation of θ+δ4
which has true value of -1.4. Furthermore, since δ5 is set to 0 as well, this
is equivalent to assume that θ+δ5 = θ+δ4. Consequently, the estimated
effect of period 5 had a bias of δ4−δ5 compared to the true value of b5.
On the other hand, the other two interaction terms shown in the results
were unbiased estimations of the treatment effect differences between
period 2 (resp. period 3) and period 4: δ2−δ4 (resp. δ3−δ4) with its true
value being 0.6 (resp. 0.3). In addition, the constant increment model also
produced unbiased estimations of the parameters including the linear
increment of the treatment effects. Finally, growth model had unbiased
estimates with nominal coverage probabilities as well.
Table 3.7 | Bias, standard deviation (SD) and the empirical coverage probabilities (CP) of
three different methods without interactions for scenario (III): Period effect and linearly
increasing treatment-period interaction.
Cluster: Marginal Cluster: Mixed H&H Model
Parameters bias (SD) CP bias (SD) CP bias (SD) CP
Treatment 0.2299 (0.0802) 22.40% 0.1808 (0.0832) 41.84% 0.1809 (0.0832) 40.60%
Intercept 0.0640 (0.1182) 89.85% 0.0052 (0.1215) 96.25% 0.0053 (0.1216) 96.25%
Period 2 0.0734 (0.0798) 83.00% 0.0836 (0.0822) 81.98% 0.0835 (0.0823) 81.15%
Period 3 0.0350 (0.0875) 90.85% 0.0181 (0.0894) 94.89% 0.0183 (0.0895) 94.40%
Period 4 0.2876 (0.0970) 21.40% 0.2720 (0.1000) 21.97% 0.2720 (0.1000) 21.10%
Period 5 0.6371 (0.1075) 00.00% 0.6296 (0.1126) 00.00% 0.6297 (0.1126) 00.00%
In scenario IV, cluster-level marginal model, cluster-level mixed effects
model, Hussey and Hughes model, and the constant increment model
all had unbiased estimations for period 2, 3, and 4 but their estimations
of period 5 and average treatment effect were biased and the coverage
probabilities of all the parameters, except for the intercept, were too lib-
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Table 3.8 | Bias, standard deviation (SD) and the empirical coverage probabilities (CP)
of three different methods with interactions for scenario (III): Period effect and linearly
increasing treatment-period interaction.
H&H model with interaction Constant increment Growth Model
Parameters bias (SD) CP bias (SD) c.p. bias (SD) CP
Treatment 0.0004 (0.1505) 95.50% 0.0055 (0.1198) 95.30% 0.0028 (0.1555) 94.75%
Intercept 0.0055 (0.1216) 96.15% 0.0055 (0.1217) 96.15% 0.0056 (0.1357) 96.40%
Period 2 0.0024 (0.0862) 95.30% 0.0025 (0.0844) 95.30%
0.0007 (0.0401) 94.40%
Period 3 0.0009 (0.1035) 94.75% 0.0015 (0.0911) 94.95%
Period 4 0.0022 (0.1486) 94.95% 0.0008 (0.1356) 95.00%
Period 5 0.2983 (0.1703) 55.30% 0.0025 (0.2267) 95.25%
Period2*trt 0.0060 (0.1867) 95.70%
∆: 0.0022 (0.0927) 95.65% 0.0004 (0.0481) 95.10%
Period3*trt 0.0031 (0.1776) 95.50%
Period4*trt 0 (N.A.) N.A.
Period5*trt 0 (N.A.) N.A.
eral. This is probably caused by the inflated variations of the estimations.
The Hussey and Hughes model with interaction terms produced unbiased
estimations of all parameters with close to nominal coverage probabilities
for the effects of period 2, 3, and 4. However, the coverage probabilities
for period 5, the treatment effect, and the interaction terms were still anti-
conservative. Furthermore, the growth model estimated the parameters
correctly. However, its coverage probabilities for the treatment effect and
the treatment-period interaction were too liberal.
Table 3.9 | Bias, standard deviation (SD) and the empirical coverage probabilities (CP) of
three different methods without interactions for scenario (IV): Period effect and random
treatment-period interaction.
Cluster: Marginal Cluster: Mixed H&H Model
Parameters bias (SD) CP bias (SD) CP bias (SD) CP
Treatment 0.0365 (0.2914) 49.40% 0.0276 (0.2975) 46.39% 0.0280 (0.2977) 45.75%
Intercept 0.0514 (0.1200) 91.20% 0.0739 (0.1231) 95.68% 0.0026 (0.1231) 95.65%
Period 2 0.0005 (0.1287) 78.10% 0.0029 (0.1338) 78.11% 0.0028 (0.1342) 77.30%
Period 3 0.0104 (0.2060) 66.00% 0.0152 (0.2099) 62.40% 0.0153 (0.2102) 61.75%
Period 4 0.0007 (0.3602) 47.55% 0.0063 (0.3620) 46.59% 0.0068 (0.3621) 45.80%
Period 5 0.0378 (0.5657) 34.50% 0.0461 (0.5795) 33.79% 0.0466 (0.5792) 33.15%




Table 3.10 | Bias, standard deviation (SD) and the empirical coverage probabilities (CP)
of three different methods with interactions for scenario (IV): Period effect and random
treatment-period interaction.
H&H model with interaction Constant increment Growth Model
Parameters bias (SD) CP bias (SD) CP bias (SD) CP
Treatment 0.0116 (0.5203) 45.75% 0.0046 (0.4375) 42.85% 0.0328 (0.8852) 33.05%
Intercept 0.0028 (0.1230) 95.80% 0.0028 (0.1230) 95.65% 0.0025 (0.1383) 96.20%
Period 2 0.0009 (0.0857) 94.75% 0.0002 (0.1014) 90.85%
0.0007 (0.0403) 94.65%
Period 3 0.0008 (0.1034) 95.20% 0.0080 (0.2069) 62.95%
Period 4 0.0032 (0.1486) 95.00% 0.0173 (0.2646) 69.90%
Period 5 0.0302 (0.7291) 37.90% 0.0693 (0.9586) 37.25%
Period2*trt 0.0274 (0.7509) 41.55%
∆: 0.0184 (0.3735) 41.30% 0.0025 (0.2381) 33.30%
Period3*trt 0.0337 (0.7366) 41.65%
Period4*trt 0 (N.A.) N.A.
Period5*trt 0 (N.A.) N.A.
the percentage of the simulations that produced significant results from
the three models, namely the Hussey and Hughes model, the constant
increment model and the growth model, are shown in Table 3.11. When
there is no interactions between treatment and period, all three models
had Type I errors less than 5%. In scenario III, all three models had larger
than 80% power. The growth model had the highest power of 100.00%
and the Hussey and Hughes model with interactions had lowest power
of 83.35%. The constant increment model performed in between. In
scenario IV with random treatment-period interactions, the Hussey and
Hughes model still maintained a power of 80.25% while the other two
models both had significantly worsened powers.
Table 3.11 | The percentages of results with p-value smaller or equal to 0.05 from the
hypothesis testing of treatment-period interaction effects for the three models with
interactions.
Scenario H&H model Constant increment Growth Model
I 04.30% 03.70% 04.60%
II 04.35% 04.50% 04.85%
III 83.35% 90.00% 100.00%
IV 80.25% 58.70% 66.70%
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3.5. DISCUSSION
In the present paper, we discussed some practical issues in terms of an-
alyzing data for a stepped wedge design at cluster level and individual
level. In general, without stringent assumptions on the absence of period
effects and period-treatment interactions, standard statistical methods
are frequently insufficient and leads to possibly incorrect interpretations
and conclusions.
Indeed in classic parallel setting, one would still expect the frequently
used models without period-treatment interaction such as the Hussey
and Hughes model to be able to estimate the average treatment effect.
However, this is no longer the case under the stepped wedge setting. This
should raise a lot of attention about the consequences of fitting a model
without the interaction but still interpret the results as in the parallel
design. Therefore, it is crucial to assess the treatment-period interaction
terms first. According to the simulation results, we recommend to use the
generalized linear mixed model of Hussey and Hughes with the inclusion
of treatment-period interaction to investigate the differences between the
specific treatment effects at different periods since it has consistent power
to detect the interactions. Even though the treatment effect at the last
period is not estimated unbiasedly in this model, the estimations of other
interaction terms can be used to aid the judgement of whether there exists
a treatment-period interaction. Furthermore, it provides opportunities
to explore the specific form of the treatment-period interactions which
allows a correct parametrization/model to be used. For instance, if the
interaction term is linear, the constant increment model proposed in
the paper or a growth model would be preferred. On the other hand,
if the interactions are truly random, there is at the moment no models
that can consistently estimate the parameters with nominal coverage




if there is sufficient numbers of periods that can provide information of
the interactions. Nevertheless, it is still unappealing to assume that the
interactions of treatment and period is random but both treatment and
period are not. A better model to deal with scenario IV for stepped wedge
design is of great interests for investigations.
It is noteworthy that the parametrization of the commonly used statis-
tical software such as the case in SAS is not the same as the ones proposed
in the presented paper. On the other hand, it is straightforward to include
interactions in a growth model but the problem becomes more complex
when the three-way interactions between treatment, period and cluster is
considered. Due to the limited space, this problem was not studies in the
present paper and further investigations is needed.
Meta-analysis methods are very strong and are serious analysis candi-
dates when period effects are non-existent. Further benefits of applying
meta-analysis methods is the ability to quantifying and testing hetero-
geneity of the effect sizes [5, 14] which is not often considered in stepped
wedge designs. Rejection of the test implies the presence of heterogeneity
of the population effects. By using random effects instead of fixed effect
meta-analysis methods one can account for this in the analysis.[26, 27]
Overall, period effect, correlation within clusters and treatment hetero-
geneities are three important questions to consider prior to the analysis
of the data in the stepped wedge design.
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